Dr. Noah Federman’s main scientific interest has been in the field of nanotechnology: developing nanoparticles to specifically target sarcomas and deliver cytotoxic chemotherapy. This novel research may lead to new breakthroughs in targeted therapies for cancer. As a member and institutional principle investigator for the Sarcoma Alliance Research Through Collaboration (SARC), Federman leads an experienced pediatric sarcoma clinical research team with an emphasis towards studying promising new agents in children with very aggressive and often fatal metastatic and refractory bone and soft tissue cancers.
Selected Cancer-Related Publications:
Bernthal NM, Federman N, Eilber FR, Nelson SD, Eckardt JJ, Eilber FC, Tap WD. Long-term results (>25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high-grade, operable osteosarcoma. Cancer. 2012 Dec 1;118(23):5888-93. Epub 2012 May 30
Anderson JL, Denny CT, Tap WD, Federman N. Pediatric sarcomas: translating molecular pathogenesis of disease to novel therapeutic possibilities. Pediatr Res. 2012 Aug;72(2):112-21.
Mitton B, Federman N. Alveolar soft part sarcomas: molecular pathogenesis and implications for novel targeted therapies. Sarcoma. 2012 Apr 8;2012:428789.
Federman N, Denny CT. Targeting liposomes toward novel pediatric anticancer therapeutics. Pediatr Res. 2010 May;67(5):514-9.
Federman N, Bernthal N, Eilber FC, Tap WD. The multidisciplinary management of osteosarcoma. Curr Treat Options Oncol. 2009 Apr;10(1-2):82-93. Epub 2009 Feb 24